The largest brain-imaging project in history has sliced and diced data from the first 5 percent of its cohort. Neurodegeneration scientists deplore the lack of AD biomarkers.
In mice, rolofylline perks up neurons laid low by aggregates of tau.
Transgenic animals develop muscle weakness and paralysis similar to people with the disease.
The kinase prevents tau degradation, raising levels and kicking off hyperphosphorylation.
A mouse that expresses ApoE only in the blood loses synapses in the brain, but appears to learn and remember normally.
Discoverer of ApoE4 risk allele died of a heart attack.
Schenk loses two-year battle with pancreatic cancer.
The LAG3 transmembrane protein latches onto fibrillar forms of the synaptic protein and ushers them into neurons. Researchers propose targeting LAG3 to slow toxic spread of misfolded forms of synuclein.
Idalopirdine failed to slow memory decline in patients with Alzheimer’s disease.
Sometimes challenged, the idea that pathogenic proteins spread through the brain got a lift from new animal model data presented at the frontotemporal dementia meeting.
Geneticists at frontotemporal dementia conference reported a new link with a ubiquitine enzyme and strengthened other gene associations.
Several such tests generated enthusiasm at the international frontotemporal dementia congress.
Researchers at an international frontotemporal dementia congress reported progress in finding markers that track disease, but no luck thus far with diagnostic markers.
Researchers reported negative findings from three trials at ICFTD 2016.
Frontotemporal Dementia: The Hard Work of Pushing Toward Trials First Round of FTD Therapeutics Fell Short, But Many More Are Up and Running Fluid NfL Shines, Tau PET Dims, in the Hunt for FTD Biomarkers Tests of Social Cognition Hold Potential as FTD ...